Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 33Recruiting 14Active not recruiting 11Terminated 9Unknown 3Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8Dermatologic 7Gastrointestinal 6Thoracic 5Head & Neck 5Sarcoma 2Lymphoid 2CNS 2Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1

Conditions

Solid Tumors 1

Interventions

Injections 9Interviews as Topic 4Cisplatin 4Carboplatin 4toripalimab 3fludarabine 3envafolimab 3Pemetrexed 3Iodine-125 3Immune Checkpoint Inhibitors 3Fluorodeoxyglucose F18 3tislelizumab 2pembrolizumab 2Paclitaxel 2Oxaliplatin 2Drug Therapy 2Cyclophosphamide 2Cryosurgery 2Capecitabine 2Blood Specimen Collection 2trastuzumab deruxtecan 1spartalizumab 1somatostatin receptor 2 1regorafenib 1olaparib 1nabiximols 1malic acid 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Nivolumab × Other solid neoplasm × Clear all
NCT07176975 2026-05-26

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Boehringer Ingelheim

Phase 1 Not yet recruiting
46 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡